Retatrutide Price and Release Date: What Is Known

Retatrutide has no legal price, because it is not approved anywhere. Eli Lilly, which makes it, says retatrutide “cannot be legally sold or marketed for human use,” and that no medicine containing it has been approved by any regulator in the world.^[1][2] Lilly plans to submit it to FDA in the first quarter of 2027. It has not announced a release date or a price. Anything sold online as retatrutide today is illegal to sell to you, and our FDA warning-letter tracker holds 21 letters to companies that sold it.

Why retatrutide has no price

A drug gets a list price when the company launches it after approval. Retatrutide has not reached that point. It is an investigational weekly injection that acts on three hormone receptors (GIP, GLP-1 and glucagon), and it is still in phase 3 testing.^[1] Lilly’s own consumer page says it “is not yet available for public use” and is “available only to participants in Lilly’s clinical trials.”^[3]

It also cannot be made by a compounding pharmacy. FDA says federal law bars pharmacies from compounding with retatrutide.^[5] Its warning letters give three reasons: the ingredient has no official USP or NF quality standard, it is not part of any approved drug, and it is missing from the short list of bulk substances pharmacies are allowed to compound with.^[9] Our explainer on what cannot legally be compounded covers those rules in full.

So the prices you find online, per vial or per month, are prices for an unverified product that someone says is retatrutide.

When retatrutide might be approved

Lilly has given one date, and it is a filing date, not a launch date. After two more phase 3 obesity trials read out in July 2026, Lilly said it is completing the manufacturing data package “required for a Biologics License Application (BLA) and plans to subsequently submit retatrutide in Q1 2027 for U.S. approval.”^[1] Lilly also said it plans global submissions for obesity, knee osteoarthritis pain and obstructive sleep apnea.

1. Filing. Lilly plans to submit the application in the first quarter of 2027.^[1]
2. FDA review. FDA’s stated goal is to act on an application within 10 months under standard review, or 6 months under priority review.^[6] FDA can also approve, ask for more data, or decline.
3. Launch and price. Only after approval would Lilly set a price and ship it to pharmacies. Lilly has not said when that would be.

Neither Lilly nor FDA has given a release date, so we do not add those steps up into one. Any site quoting a specific launch month is guessing. The trial program behind the filing is covered in retatrutide: what the evidence shows and retatrutide’s phase 3 and the gray market, and the wider pipeline on our GLP-1 pipeline tracker.

What approved drugs in the same family cost today

Retatrutide’s eventual price is unknown, so the useful number is what an approved alternative costs now. Lilly sells Zepbound (tirzepatide), its approved weight-loss injection, to self-pay patients starting at $299 a month for the 2.5 mg dose through LillyDirect, in a vial or KwikPen.^[10] Higher doses cost more; the full dose-by-dose breakdown is on our Zepbound cost page. This is an anchor for today, not a forecast of what retatrutide will cost.

For how the two drugs compare on what is known so far, see retatrutide vs Zepbound; for what the trials recorded on safety, retatrutide side effects.

What “retatrutide for sale” really is

Most retatrutide sold online comes as a powder in a vial, with a label claiming it is meant for lab research rather than for people, and often under a code name. FDA letters record sellers listing it under names such as “Reta,” “GLP-1-R peptide,”^[8] “GLP1-R” and “GLP-3 RT” (each letter is linked in the table below). The research label does not make the sale legal. FDA says it has warned companies that put false research-only labels on retatrutide and similar drugs while selling them straight to consumers, complete with dosing instructions. It urges people not to buy these products, which it describes as of unknown quality and possibly harmful.^[5]

Some sellers skip the research label and market retatrutide as a compounded prescription. One website told buyers its “Compounded Retatrutide” was the “Active Ingredient in Mounjaro and Zepbound” and described “the standard, FDA-approved dosing schedule for Retatrutide.” Neither is true. Retatrutide is not in either drug, and there is no FDA-approved dose, because there is no approval; the only tested schedules are the trial protocols. FDA called the claims false or misleading.^[11]

Lilly is also suing. In August 2026 it filed six lawsuits against U.S. sellers, including research-use-only sellers, a medical spa and a compounding pharmacy, and said it had reported more than 14,000 websites, ads and listings marketing retatrutide in over 100 countries.^[2] Its chief medical officer said what is sold on the black market “is not a medicine,” calling it “entirely unverified, unapproved and not worth the risk.”^[2] Our guide to research-chemical GLP-1 listings explains the same pattern for tirzepatide.

The FDA warning letters that name retatrutide

Our FDA warning-letter tracker holds 21 letters that name retatrutide, dated December 2024 through August 2026. We read the full text of each one on fda.gov. FDA has sent others we have not yet added, so treat this as a floor, not a total.

FDA’s own summary matches this spread. It says it has warned telehealth companies for marketing retatrutide, ingredient distributors for selling it to compounders, and outsourcing facilities for repackaging it.^[5] Our analysis of what FDA’s GLP-1 warning letters say covers the broader set.

What the sellers we review list

A few telehealth sellers we review offer something they call retatrutide. Four list a monthly price for it, from $170 to $499. We report those figures only to show the market exists. They are not prices for an approved medicine, and they tell you nothing about what is in the vial.

Flo Clinic, a New Jersey mobile IV clinic with a telehealth GLP-1 program, sells retatrutide as a research compound with no prescription or doctor visit, and tells buyers to inject it weekly at home.

What to do instead today

• Take an approved drug. Tirzepatide (Zepbound) and semaglutide (Wegovy) are approved for weight loss. Our tirzepatide providers board compares where to get tirzepatide, and the tirzepatide drug page covers the approved products.
• Join a trial if you want retatrutide itself. That is the main legal route. Lilly also lists an expanded-access program, limited to adults with a BMI of 35 or more despite top-dose treatment and two or more serious complications, who cannot join a trial.^[3][4][13] ClinicalTrials.gov lists the studies; on September 27, 2026 it showed two retatrutide studies recruiting.^[12]
• Read the research, not the sales page. Our top retatrutide studies list collects the published trials, including the one phase 3 trial published in a journal so far.^[7]